123 related articles for article (PubMed ID: 32463773)
1. Introduction: Pharmacy Reimbursement.
Greenwood BC
J Manag Care Spec Pharm; 2020 Jun; 26(6):702. PubMed ID: 32463773
[TBL] [Abstract][Full Text] [Related]
2. Evolution of the Pharmacy Benefit Manager/Community Pharmacy Relationship: An Opportunity for Success.
Taddei-Allen P
J Manag Care Spec Pharm; 2020 Jun; 26(6):708-710. PubMed ID: 32463767
[TBL] [Abstract][Full Text] [Related]
3. To Reform Pharmacy Reimbursement Begin with the Basics.
Rupp MT
J Manag Care Spec Pharm; 2020 Jun; 26(6):713-715. PubMed ID: 32463772
[TBL] [Abstract][Full Text] [Related]
4. Medication review and patient counselling at discharge from the hospital by community pharmacists.
Hugtenburg JG; Borgsteede SD; Beckeringh JJ
Pharm World Sci; 2009 Dec; 31(6):630-7. PubMed ID: 19649720
[TBL] [Abstract][Full Text] [Related]
5. Understanding the effects of Medicare Part D from key stakeholders' perspectives: Important progress, but abundant research opportunities remain.
Urmie JM; Doucette WR
Res Social Adm Pharm; 2010 Jun; 6(2):85-9. PubMed ID: 20511107
[No Abstract] [Full Text] [Related]
6. Can a pharmacist reduce annual costs for Medicare Part D enrollees?
Alston G; Hanrahan C
Consult Pharm; 2011 Mar; 26(3):182-9. PubMed ID: 21402518
[TBL] [Abstract][Full Text] [Related]
7. AMCP Partnership Forum: What's Next for Specialty Medication Benefit Design and Reimbursement.
J Manag Care Spec Pharm; 2020 Oct; 26(10):1206-1213. PubMed ID: 32780612
[TBL] [Abstract][Full Text] [Related]
8. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
Goedken AM; Urmie JM; Farris KB; Doucette WR
Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
[TBL] [Abstract][Full Text] [Related]
9. Impact of Medicare Part D on independent and chain community pharmacies in rural Illinois--A qualitative study.
Bono JD; Crawford SY
Res Social Adm Pharm; 2010 Jun; 6(2):110-20. PubMed ID: 20511110
[TBL] [Abstract][Full Text] [Related]
10. Factors associated with independent pharmacy owners' satisfaction with Medicare Part D contracts.
Zhang S; Doucette WR; Urmie JM; Xie Y; Brooks JM
Res Social Adm Pharm; 2010 Jun; 6(2):121-9. PubMed ID: 20511111
[TBL] [Abstract][Full Text] [Related]
11. Cost-utility analysis of a medication review with follow-up service for older adults with polypharmacy in community pharmacies in Spain: the conSIGUE program.
Jódar-Sánchez F; Malet-Larrea A; Martín JJ; García-Mochón L; López Del Amo MP; Martínez-Martínez F; Gastelurrutia-Garralda MA; García-Cárdenas V; Sabater-Hernández D; Sáez-Benito L; Benrimoj SI
Pharmacoeconomics; 2015 Jun; 33(6):599-610. PubMed ID: 25774017
[TBL] [Abstract][Full Text] [Related]
12. Capitation reimbursement for pharmacy services: a dissenting view.
Gosselin RA
Med Mark Media; 1980 Oct; 15(10):51-6. PubMed ID: 10249122
[No Abstract] [Full Text] [Related]
13. Impact of pharmacy benefit design on prescription drug utilization: a fixed effects analysis of plan sponsor data.
Roebuck MC; Liberman JN
Health Serv Res; 2009 Jun; 44(3):988-1009. PubMed ID: 19187183
[TBL] [Abstract][Full Text] [Related]
14. The challenge of Medicare Part D for community pharmacies.
Stone D
J Manag Care Pharm; 2009 Mar; 15(2):171-2. PubMed ID: 19236134
[No Abstract] [Full Text] [Related]
15. A comparison of mail-service and retail community pharmacy claims in 5 prescription benefit plans.
Clark BE; Siracuse MV; Garis RI
Res Social Adm Pharm; 2009 Jun; 5(2):133-42. PubMed ID: 19524861
[TBL] [Abstract][Full Text] [Related]
16. Third-party reimbursement for generic prescription drugs: The prevalence of below-cost reimbursement in an environment of maximum allowable cost-based reimbursement.
Murry L; Gerleman B; Urick B; Urmie J
J Am Pharm Assoc (2003); 2018; 58(4):421-425. PubMed ID: 29861152
[TBL] [Abstract][Full Text] [Related]
17. Employer and Plan Sponsor Views on Pharmacy Reimbursement.
Stull M; Gupton C
J Manag Care Spec Pharm; 2020 Jun; 26(6):710-712. PubMed ID: 32463776
[TBL] [Abstract][Full Text] [Related]
18. PDP or MA-PD? Medicare part D enrollment decisions in CMS Region 25.
Cline RR; Worley MM; Schondelmeyer SW; Schommer JC; Larson TA; Uden DL; Hadsall RS
Res Social Adm Pharm; 2010 Jun; 6(2):130-42. PubMed ID: 20511112
[TBL] [Abstract][Full Text] [Related]
19. Challenges for Managed Care from 340B Contract Pharmacies.
Fein AJ
J Manag Care Spec Pharm; 2016 Mar; 22(3):197-203. PubMed ID: 27003548
[TBL] [Abstract][Full Text] [Related]
20. Price Is Right: Exploring Prescription Drug Coverage Barriers for Irritable Bowel Syndrome Using Threshold Pricing Analysis.
Shah ED; Chang L; Lembo A; Staller K; Curley MA; Chey WD
Dig Dis Sci; 2021 Dec; 66(12):4140-4148. PubMed ID: 33433804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
